Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Parkinson 's disease Market Will Reflect Significant Growth Prospects During the Study Period [2018-2030], Anticipates DelveInsight

      Parkinson's Disease Market will upsurge due to the increasing prevalent population and the launch of gene therapies and several other potential therapies

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Apr 14, 2021, 12:30 ET

      Share this article

      Share this article


      LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight's "Parkinson's Disease Market" report provides a thorough comprehension of the Parkinson's Disease, historical and forecasted epidemiology, and the Parkinson's Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Parkinson's Disease market report also proffers an analysis of the current Parkinson's Disease treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

      Key takeaways of the Parkinson's Disease Market Research Report 

      • The increase in Parkinson 's disease prevalent population in the 7MM and the expected entry of premium price assets will influence market size growth.
      • In February 2021, the US FDA approved GOCOVRI (amantadine) as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes. It is also approved to treat dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
      • In May 2020, the US FDA approved KYNMOBI (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in Parkinson's Disease patients.
      • Levodopa is the most preferred therapy for Parkinson's Disease treatment and its symptoms. 
      • The US FDA, in April 2020, has approved Ongentys (Opicapone) as an oral, add-on daily treatment for Parkinson's disease patients experiencing off periods while on a levodopa/carbidopa regime. 
      • Other than levodopa, dopamine agonists followed by amantadine, MAO-B inhibitors, and several others (COM-T inhibitors, anticholinergic inhibitors) accounted for the Parkinson's Disease significant market share in the US in 2017.
      • A strong pipeline of drugs is being developed by the manufacturers such as Prevail Therapeutics, Axovant Gene Therapies, Denali Therapeutics, Luye Pharma, Sumitomo Dainippon Pharma, BIAL, AbbVie, Impax Laboratories (Amneal Pharmaceuticals), Supernus Pharmaceuticals, Intec Pharma, MeiraGTx Limited, Axovant Sciences, NeuroDerm, Intracellular Therapies, Integrative Research Laboratories AB (IRLAB), International Stem Cell Corporation, Living Cell Technologies, Pharma Two B Ltd, and others that will offer lucrative opportunities for the Parkinson's disease market to grow. 

      For further information on Market Impact by Therapies, visit: Parkinson's Disease Treatment Market Size 

      Parkinson's Disease is a progressive disorder caused by degeneration of nerve cells in the substantia nigra, which controls movement. Most people start developing Parkinson's Disease symptoms when they are over 50, although some individuals experience symptoms when under 40.

      According to DelveInsight's analysts, the total diagnosed Parkinson's Disease prevalent population in the 7MM is expected to rise to 3,284,084 cases in 2030 during the study period [2018–2030]. In 2020, the US accounted for 38.36% of the total diagnosed prevalent cases of Parkinson's Disease in the 7MM. The males appear to be predisposed to Parkinson's Disease, so a higher percentage of prevalence was observed in males than females. 

      The Parkinson's Disease Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

      • Total Diagnosed Parkinson's Disease Prevalent Pool
      • Gender-specific Diagnosed Parkinson's Disease Prevalent Pool
      • Type-specific Diagnosed Parkinson's Disease Prevalent Pool
      • Age-specific Diagnosed Parkinson's Disease Prevalent Pool
      • Stage-specific Diagnosed Parkinson's Disease Prevalent Pool
      • Treatable Patient Pool of Parkinson's Disease 

      Get a sample copy of this report: Parkinson's Disease Market Landscape

      Parkinson's Disease Treatment Market 

      There is currently no cure, but treatments are available to help relieve Parkinson's Disease symptoms. These treatments include medication, surgery, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). 

      The approved medication therapies are categorised into seven groups that comprise Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine. 

      Medication can be utilised to improve the main symptoms of Parkinson's Disease. But not all the medications available are helpful for everyone, and the short- and long-term effects are different. Three main types of medication are usually used: Carbidopa-levodopa, Carbidopa-levodopa infusion, and Dopamine agonists.

      Treatment with monoamine oxidase-B (MAO-B) inhibitors, amantadine (Symmetrel), or anticholinergics may improve mild symptoms; but, most patients require levodopa or a dopamine agonist. The American Academy of Neurology (AAN) recommends levodopa or a dopamine agonist when dopaminergic treatment is needed, depending on the need to improve motor disability or decrease motor complications (dopamine agonists cause fewer motor complications). The most often prescribed combination drugs are carbidopa/levodopa (cocareldopa [sinemet, pharmacopa, atamet]) and benserazide/levodopa (co-beneldopa [Madopar]). Levodopa with a DOPA decarboxylase inhibitor is mostly a first-line treatment option for Parkinson's Disease. 

      For advanced Parkinson's Disease patients, mostly surgeries are preferred. Most of the treatments are aimed at benefiting the tremor or rigidity that emerges from the disease. In some patients, surgery may reduce the amount of medication that is required to control the symptoms. Three types of surgeries may be performed for Parkinson's disease, including the following: Lesion surgery, deep brain stimulation (DBS), and neural grafting or tissue transplants. Deep brain stimulation was approved in 2002 as adjunctive therapy in reducing motor fluctuation in advanced Parkinson disease.

      Parkinson's Disease Emerging Therapies Along with Key Players

      • SPN-830 (apomorphine infusion pump): Supernus Pharmaceuticals
      • Accordion Pill Carbidopa/Levodopa: Intec Pharma
      • P2B001: Pharma Two B Ltd.
      • IPX203: Impax Laboratories (Amneal Pharmaceuticals)
      • LY03003: Luye Pharma
      • ABBV-951: AbbVie
      • Allo iPS cell-derived dopamine neural progenitor: Sumitomo Dainippon Pharma
      • AAV-GAD: MeiraGTx Limited
      • AXO-Lenti-PD (OXB-102): Axovant Sciences
      • ND0612: NeuroDerm
      • Lenrispodun (ITI-214): Intracellular Therapies
      • Pirepemat (IRL752): Integrative Research Laboratories AB (IRLAB)
      • PR001: Prevail Therapeutics
      • ISC-hpNSC: International Stem Cell Corporation 

      And several others.

      In conclusion, the development of adherence-friendly drug formulations, development of the drug for better treatment of motor symptoms, and gene therapy and stem cell therapy will drive Parkinson's Disease Market Growth, whereas inadequate knowledge of Parkinson's Disease pathophysiology, lack of diagnostic measures and methods, and lack of efficacy of existing therapies will hamper the growth of Parkinson's Disease market size. 

      Scope of the Parkinson's Disease Market Insight  Report 

      • Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
      • Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
      • Parkinson's Disease Markets Segmentation: By Geographies and By Parkinson's Disease Therapies (Historical and Forecasted, Current and Upcoming) 
      • Dominant Market Companies investigating its candidates for Parkinson's Disease: Prevail Therapeutics, Axovant Gene Therapies, Denali Therapeutics, Luye Pharma, Sumitomo Dainippon Pharma, BIAL, AbbVie, Impax Laboratories (Amneal Pharmaceuticals), Supernus Pharmaceuticals, Intec Pharma, MeiraGTx Limited, Axovant Sciences, NeuroDerm, Intracellular Therapies, Integrative Research Laboratories AB (IRLAB), International Stem Cell Corporation, Living Cell Technologies, Pharma Two B Ltd, and several others.
      • Analysis: Comparative and conjoint analysis of emerging therapies. 
      • Case Studies
      • KOL's Views
      • Analyst's View

      Request for a Webex demo of the report @ Parkinson's Disease Treatment Market Size

      Table of Contents 

      1

      Parkinson's Disease Key Insights

      2

      Executive Summary of Parkinson's Disease  

      3

      Parkinson's Disease Market Overview at a Glance

      4

      Parkinson's Disease Case Reports 

      5

      Parkinson's Disease Epidemiology and Patient Population

      6

      Country Wise-Epidemiology of Parkinson's Disease

      6.1

      The United States Epidemiology

      6.2

      EU5 Countries Epidemiology

      6.2.1

      Germany

      6.2.2

      France

      6.2.3

      Italy

      6.2.4

      Spain

      6.2.5

      The United Kingdom

      6.3

      Japan Epidemiology

      7

      Treatment and Management of Parkinson's Disease

      8

      Parkinson's Disease Unmet Needs

      9

      Parkinson's Disease Marketed Drugs

      9.1

      Istradefylline (KW-6002): Kyowa Kirin

      9.2

      Opicapone: BIAL

      9.3

      Gocovri: Adamas Pharmaceuticals

      9.4

      Xadago: Zambon SpA

      9.5

      Osmolex ER: Osmotica Pharmaceutical

      9.6

      Duopa (Duodopa, ABT-SLV187): AbbVie

      9.7

      Rytary: Impax Laboratories (Amneal Pharmaceuticals)

      9.8

      Inbrija: Acorda Therapeutics

      9.9

      Nuplazid: ACADIA Pharmaceuticals Inc.

      10

      Parkinson's Disease Emerging Drugs

      10.1

      Apomorphine Infusion: US WorldMeds LLC

      10.2

      Accordion Pill Carbidopa/Levodopa: Intec Pharma

      10.3

      P2B001: Pharma Two B Ltd.

      10.4

      IPX203: Impax Laboratories (Amneal Pharmaceuticals)

      10.5

      LY03003: Luye Pharma

      10.6

      ABBV-951: AbbVie

      10.7

      Allo iPS cell-derived dopamine neural progenitor: Sumitomo Dainippon Pharma

      10.8

      Solriamfetol (JZP-110): Jazz Pharmaceuticals

      10.9

      NBIb-1817 (VY-AADC): Neurocrine Biosciences/Voyager Therapeutics

      10.10

      AAV-GAD: MeiraGTx Limited

      10.11

      AXO-Lenti-PD (OXB-102): Axovant Sciences

      10.12

      ND0612: NeuroDerm

      10.13

      ITI-214: Intracellular Therapies

      10.14

      IRL752: Integrative Research Laboratories AB (IRLAB)

      10.15

      PR001: Prevail Therapeutics

      10.16

      ISC-hpNSC: International Stem Cell Corporation

      11

      7MM Parkinson's Disease Market Analysis

      11.1

      The United States Parkinson's Disease Market Size

      11.2

      EU-5 Parkinson's Disease Market Size

      11.2.1

      Germany Market Size

      11.2.2

      France Market Size

      11.2.3

      Italy Market Size

      11.2.4

      Spain Market Size

      11.2.5

      The United Kingdom Market Size

      11.3

      Japan Parkinson's Disease Market Size

      12

      Parkinson's Disease Market Drivers

      13

      Parkinson's Disease Market Barriers

      14

      SWOT Analysis of Parkinson's Disease

      15

      KOL Views

      16

      Parkinson's Disease Market Access and Reimbursement

      17

      Appendix

      18

      DelveInsight Capabilities

      19

      Disclaimer

      20

      About DelveInsight

      Browse full report with detailed TOC with charts, figures, tables @ Parkinson's Disease Treatment Market Report

       View Related Reports      

      • Parkinson's Disease Levodopa-Induced Dyskinesia Market 

      DelveInsight's Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. 

      • Parkinson's Disease Psychosis Market

      DelveInsight's Parkinson's disease psychosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

      • Parkinson's Disease Epidemiology Forecast 

      DelveInsight's Parkinson's Disease - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Parkinson's Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

      • Parkinson's Disease Psychosis Epidemiology Forecast

      DelveInsight's Parkinson's disease psychosis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Parkinson's disease psychosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

      • Parkinson's Disease Pipeline Insights

      Parkinson's Disease Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Parkinson's Disease market.

      • Parkinson's Disease Psychosis Pipeline Insights

      Parkinson's disease psychosis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Parkinson's disease psychosis market.

      About DelveInsight

      DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

      Contact Us:

      Shruti Thakur
      [email protected] 
      +1(919)321-6187
      www.delveinsight.com 

      Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Publishing & Information Services

      Publishing & Information Services

      Surveys, Polls and Research

      Surveys, Polls and Research

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.